Clinical trials: Epithelial-Mesenchymal Transition
Colorectal Neoplasms
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC)…
- Trial name
- NCT04515394
- Testing
- Tepotinib, Cetuximab
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Prostatic Neoplasms, Prostatic Adenoma
Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique
1. To elucidate the role of CTC detection in the evaluation of risk level in PCa patients, and establish a mathematic model for predicting the pathological status. 2.
- Trial name
- NCT02940977
- Testing
- Blood draws
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Non-Squamous Non-Small Cell Lung Cancer
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in…
- Trial name
- NCT06417008
- Testing
- HS-20117, Aumolertinib
- Where
- 2 sites in China
- Volunteers
- 1,080 people
- Sponsor
- Hansoh BioMedical R&D Company
Non-Small-Cell Lung Cancer
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy)…
- Trial name
- CHRYSALIS (NCT02609776)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 69 sites in United States, Australia and 8 more
- Volunteers
- 751 people
- Sponsor
- Janssen Research & Development, LLC
Neoplasms, Neoplasm Metastasis
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
- Conditions
- Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT05176665
- Testing
- EMB-01
- Where
- 14 sites in United States, China
- Volunteers
- 152 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Oral Submucous Fibrosis
Epithelial Mesenchymal Transition Markers in OSMF
Oral Sub mucous Fibrosis (OSMF) is essentially an imbalance between collagen metabolism and wound healing mechanism induced by arecanut chewing habit.
- Trial name
- NCT03732872
- Testing
- Biopsy tissue analysis, Saliva analysis
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- The Oxford Dental College, Hospital and Research Center, Bangalore, India
Epithelial-Mesenchymal Transition, Circulating Tumor Cells
Aspirin on CTCs of Advanced Breast and Colorectal Cancer
The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.
- Trial name
- ACABC (NCT02602938)
- Testing
- Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Provincial People's Hospital
Head-and-Neck Squamous Cell Carcinoma
Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.
Investigation of the molecular mechanism and clinical significance of the interplay between Twist1 and other EMT regulators through microRNA-29 family.
- Trial name
- NCT01927354
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Healthy
Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
This is a Phase I, open label, randomized, crossover trial to investigate the relative bioavailability of tepotinib in healthy volunteers.
- Trial name
- NCT03021642
- Testing
- Tepotinib test (Treatment Period 1), Tepotinib reference (Treatment Period 2), Tepotinib reference (Treatment Period 1)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany